Patenting Antibody‑drug Conjugates (adcs) in the UK (2026): Patentability, Claim Drafting, Spcs & FTO

Antibody-drug conjugate patents uk strategy has moved to the centre of life-sciences portfolio planning as a new generation of targeted oncology therapeutics reaches commercialisation. ADCs combine the selectivity of a monoclonal antibody with the cytotoxic power of a small-molecule payload, joined by a precisely engineered linker, a hybrid that straddles the chemical and biological patenting worlds and attracts some of the most valuable, and most contested, intellectual property in the sector. With evolving EPO and UK Intellectual Property Office (UKIPO) practice on biologics claim formats, and supplementary protection certificate (SPC) procedures that have continued to develop following the UK’s departure from the EU, filing and exclusivity decisions taken today will determine the commercial runway for products launching years from now.

This practical guide sets out the patentability tests, component-by-component claim strategies, SPC eligibility and timing considerations, and a freedom-to-operate (FTO) framework for in-house teams navigating antibody-drug conjugate patents uk decisions.

Why ADC patents matter now, including recent SPC and EPO developments

ADCs are among the most commercially significant therapeutic classes in modern oncology, and the economics of each approved product can be very substantial. That commercial weight makes the surrounding patent estate a critical strategic asset, and a magnet for opposition and revocation challenges. Because an ADC is a composite of distinct inventive elements, protection can be layered across antibody, linker, payload, conjugation chemistry and manufacturing, giving thoughtful applicants multiple overlapping lines of defence but also multiple potential points of attack.

The timing of this guidance is deliberate. UKIPO SPC practice has continued to adapt following the UK’s departure from the EU framework, and applicants must now read current UKIPO guidance carefully when deciding which product within an ADC should anchor an SPC application. At the same time, EPO examination practice on antibody and combination claims continues to focus closely on sufficiency and added-matter requirements. Teams that locked in a claim and exclusivity strategy some years ago should revisit it. The sections below translate the primary legal sources, the Patents Act 1977, the European Patent Convention, EPO Guidelines, UKIPO SPC guidance and the Human Medicines Regulations 2012, into practical steps for antibody-drug conjugate patents uk planning.

Patentability of ADCs in the UK, legal tests and practical checkpoints

The threshold question in-house teams ask is simple: can you patent an antibody-drug conjugate in the UK? The answer is yes, provided the invention satisfies the ordinary statutory requirements. The complexity lies not in whether an ADC is patentable in principle, but in how to frame claims that are both broad enough to be commercially meaningful and narrow enough to survive validity attacks.

Statutory basis under the Patents Act 1977 and the EPC

Patentability in the UK derives from the Patents Act 1977, which sets out the requirements of novelty, inventive step, industrial applicability and sufficiency of disclosure. For applications routed through the European Patent Office, the parallel framework is the European Patent Convention, supplemented by the EPO Guidelines for Examination, which give detailed practice guidance on how examiners assess biotechnology inventions, antibody claims and combination inventions. Most UK-facing ADC portfolios are prosecuted through the EPO and validated in the UK, so applicants must satisfy both the statutory text of the Act and the examination practice reflected in the Guidelines.

Novelty and inventive step for ADCs as combination inventions

An ADC is, by its nature, a combination invention. Novelty is rarely the principal obstacle where a specific antibody-linker-payload combination has not been disclosed before. The harder test is inventive step. Examiners will ask whether the skilled person, armed with a known antibody, a known class of linker and a known cytotoxic payload, would have arrived at the claimed conjugate without inventive effort. The strongest inventive-step positions rest on a demonstrated unexpected technical effect, improved therapeutic index, greater serum stability, reduced off-target toxicity, or a drug-to-antibody ratio that delivers a surprising efficacy or safety benefit. Where each component is individually known, the applicant must articulate why their specific combination produces a result the prior art did not predict.

Sufficiency and industrial applicability for complex biologics

Sufficiency is frequently the decisive battleground for antibody-drug conjugate patents uk. Under the Patents Act 1977 and corresponding EPC requirements, the specification must disclose the invention clearly and completely enough for the skilled person to perform it across the full scope of the claim. For broad conjugate claims, this means the application must support the breadth claimed with enabling examples. A claim covering a wide genus of linkers or payloads, backed by only a single working example, is exposed to a sufficiency attack. The practical tip is to balance claim breadth against enablement from the outset: file with a strong, representative set of examples and a fallback claim hierarchy so that if the broadest claim fails, narrower, well-supported positions remain.

Industrial applicability is seldom contentious for a therapeutic conjugate, but the specification should still articulate a credible medical use.

Component patentability, antibody, linker, payload and conjugation methods

One of the most important strategic insights for antibody-drug conjugate patents uk is that each structural component can, in principle, be protected independently. A layered approach, claiming the conjugate as a whole and separately protecting the antibody, the linker chemistry, the payload and the conjugation process, builds redundancy into the estate so that invalidation of one claim does not collapse the entire position.

Antibody core and sequence claims

The antibody is the targeting engine of the ADC and often the component with the clearest inventive contribution. Antibodies can be claimed by reference to their complementarity-determining region (CDR) sequences, by full variable-domain sequences, or functionally, for example, by the epitope they bind or by a defined binding affinity. Sequence-defined claims give strong, enforceable protection but can be designed around by competitors who modify residues outside the claimed sequences. Functional claims capture a broader range of variants but attract heightened sufficiency scrutiny at the EPO, which expects the application to enable the skilled person to identify functionally equivalent antibodies without undue burden.

Where sequences are claimed, ensure the sequence listing is complete and compliant, as deficiencies here can undermine otherwise valid claims. A common drafting pattern pairs a broad functional antibody claim with narrower sequence-defined fallbacks.

Linker chemistry

Linkers determine how and where the payload is released, and innovation in linker design is frequently the heart of an ADC’s advantage. Linkers may be claimed by chemical structure, by a defined class (for example, cleavable versus non-cleavable), or by functional properties such as plasma stability or pH-dependent cleavage. A structure-defined linker claim gives clear scope but may be narrow; a class-based claim is broader but more vulnerable to obviousness arguments if the chemistry is well known. The strongest linker claims tie a specific structural motif to a demonstrated functional benefit, for example a linker that confers a quantified stability improvement in circulation.

Platform developers should consider protecting the linker independently of any particular antibody or payload, so the innovation can be asserted across multiple products.

Payload chemistry versus formulation

The cytotoxic payload is a small molecule and is patented under conventional chemistry principles. If the payload is a new chemical entity, it may support strong composition-of-matter protection with independent market value. More often, however, the payload belongs to a known cytotoxic class, maytansinoids, auristatins, calicheamicins and the like, in which case earlier small-molecule patents may already cover it, creating overlapping rights and FTO issues. Where the payload itself is not novel, the inventive contribution shifts to the payload’s incorporation into the conjugate, to novel payload derivatives optimised for conjugation, or to the formulation. Distinguishing a payload composition claim from a formulation claim is important: the former protects the molecule, the latter protects a particular pharmaceutical presentation.

Conjugation methods and manufacturing claims

Conjugation chemistry, the process of attaching payload to antibody via the linker, and controlling the drug-to-antibody ratio, is often where real manufacturing know-how resides. Method and manufacturing claims are harder for competitors to circumvent on a technical level and can underpin process-based remedies. Their weakness is detectability: proving that a competitor uses a claimed process is far harder than proving they sell a claimed product. For that reason, conjugation and manufacturing claims generally serve as valuable defensive or backup positions within a broader estate rather than as the sole line of protection. A robust antibody-drug conjugate patents uk strategy claims the conjugation method alongside, not instead of, product and component claims.

Drafting robust ADC claims for the EPO and UKIPO

Knowing which components are patentable is only the starting point. The decisive question for most teams is how ADC claims should be drafted to survive EPO examination and subsequent UK challenges. The answer lies in a disciplined claim hierarchy, a two-track breadth strategy, and careful attention to support and added-matter constraints.

Claim drafting strategies: a layered hierarchy

Effective ADC claim drafting works through a layered hierarchy so that protection remains intact even if the broadest claims are invalidated. A typical hierarchy proceeds through:

• Composition claims. The conjugate as a whole, antibody, linker and payload, providing the broadest product protection aligned with the commercial article.
• Component claims. Separate claims to the antibody (by sequence and by function), the linker (by structure and by class), and the payload, each standing independently.
• Method of conjugation claims. The process of producing the conjugate, including control of the drug-to-antibody ratio.
• Use and therapeutic claims. Second-medical-use or purpose-limited claims directed to treatment of a specific indication or patient population.
• Manufacturing claims. Downstream process and formulation steps that protect scale-up and commercial supply.

Two-track strategy: broad composition plus narrow fallbacks

A defensible approach at the EPO is a two-track strategy. Track A is a well-supported composition claim that captures the core product and gives the broadest commercially useful scope. Track B comprises narrower sequence, linker and method claims that function as fallbacks. If an opponent succeeds against the broad composition claim on sufficiency or inventive-step grounds, the applicant can retreat to the narrower, more thoroughly enabled claims without losing all protection. Each category in both tracks should be supported by enabling examples in the specification, the EPO will not permit a breadth of claim that the disclosure does not substantiate.

Concrete claim templates

The following generic templates illustrate the drafting formats most commonly deployed for antibody-drug conjugate patents uk. They are illustrative structures, not model claims for any specific product:

• Composition (conjugate) claim. “An antibody-drug conjugate comprising an antibody covalently linked, via a linker, to a cytotoxic payload, wherein [defined structural and/or functional features].”
• Antibody-by-sequence claim. “An antibody comprising heavy and light chain CDR sequences as set out in SEQ ID NOs: [x–y].”
• Antibody-by-function claim. “An antibody that binds to [target antigen] at [defined epitope] with a dissociation constant of less than [value].”
• Linker-by-structure claim. “A linker of formula [structural formula] comprising a [cleavable/non-cleavable] moiety.”
• Payload substructure claim. “A cytotoxic payload comprising the substructure [chemical substructure] conjugatable at [defined position].”
• Conjugation method claim. “A method of producing an antibody-drug conjugate comprising conjugating [payload] to [antibody] via [linker] under conditions providing a drug-to-antibody ratio of [range].”

Examination and amendment tactics

During prosecution, the twin dangers are insufficient support and added matter. Under the EPC and the EPO Guidelines, any amendment must be directly and unambiguously derivable from the application as filed; an amendment that introduces subject matter not originally disclosed will be refused and, if it survives to grant, can become a ground of revocation. The practical discipline is to draft the original application with a rich set of fallback positions, intermediate generalisations expressly supported, and dependent claims that anticipate the amendments you may need. When responding to novelty objections, narrow by reference to features already disclosed; when responding to inventive-step objections, emphasise the unexpected technical effect and anchor it to data in the specification.

Because EPO practice on antibody sufficiency can be demanding, functional claims in particular should be accompanied by guidance in the specification enabling the skilled person to reach the full claimed scope.

SPCs for ADCs, eligibility, timing and recent developments

A granted patent protects an ADC for up to twenty years from filing, but regulatory review consumes much of that term before any sales begin. Supplementary protection certificates can restore a period of effective exclusivity after patent expiry, and for high-value ADCs that extension can be commercially very significant. Getting SPC strategy right is therefore inseparable from antibody-drug conjugate patents uk planning.

SPC basics and legal framework

In broad terms, an SPC requires a basic patent in force, a valid UK marketing authorisation for the product, and that the product has not already been the subject of an SPC. The application must be filed within the deadlines tied to grant of the patent and grant of the marketing authorisation. The marketing authorisation regime that underpins eligibility is governed by the Human Medicines Regulations 2012, and practical questions of product naming and authorisation scope engage MHRA practice. Because the SPC ties exclusivity to a specific authorised product, the definition of that product is where ADC complexity concentrates. Applicants should consult current UKIPO guidance for the applicable conditions, deadlines and procedure.

Which product is the “product” for SPC purposes?

An ADC presents a genuine puzzle: is the SPC-relevant product the antibody active ingredient, the payload, or the conjugate as an integrated whole? The answer matters because it determines which basic patent can support the SPC and how broadly the resulting certificate protects against competitors. Where the conjugate is authorised and marketed as a single active substance, the conjugate is the natural candidate. But if the antibody or the payload is independently characterised in the marketing authorisation, alternative SPC strategies may be worth considering. Applicants should map, early in development, how the product will be described in the marketing authorisation and product information, because that description shapes which SPC is available.

Recent changes and practical impact

UKIPO SPC practice has continued to develop following the UK’s departure from the EU, and applicants should consult the current UKIPO guidance rather than rely on older assumptions about product definition, filing procedure and the interaction between the basic patent and the authorisation. The practical effect for ADC teams is that SPC decisions should be taken early and revisited against the live guidance: the choice of which patent to designate, how the authorised product is defined, and the precise filing timing all carry considerable weight. Continued scrutiny of product definitions for complex conjugates makes early alignment between regulatory and patent functions essential.

A strategic decision tree

In practice, SPC planning for an ADC should proceed through a sequence of questions: Which patents are in force and could serve as the basic patent, the conjugate patent, the antibody patent, or the payload patent? How is the product defined in the marketing authorisation? Which single SPC gives the broadest and most durable protection, given that the product can generally be the subject of only one certificate? And does the filing timing satisfy the deadlines running from patent grant and authorisation? Working through this tree before authorisation, rather than after, avoids forfeiting an extension that can be worth years of exclusivity.

Freedom-to-operate and post-grant risk management for antibody-drug conjugate patents uk

Owning a strong patent estate does not guarantee the freedom to sell the product. Because an ADC incorporates separately patentable components, a competitor’s antibody, linker, payload or process patent may block commercialisation even where your own conjugate is validly patented. A structured FTO exercise is indispensable before launch.

A twelve-point FTO checklist

In-house teams planning the commercialisation of an ADC should work systematically through the following checklist:

1. Search composition-of-matter patents covering the conjugate as a whole.
2. Search antibody sequence and functional claims in sequence databases and patent literature.
3. Search linker chemistry patents, including class-based and structure-based claims.
4. Search payload and payload-derivative patents, including earlier small-molecule rights.
5. Search conjugation method and process patents.
6. Search manufacturing, purification and scale-up patents.
7. Search formulation and pharmaceutical presentation patents.
8. Identify SPCs and regulatory exclusivities (data and market exclusivity) attaching to competitor products.
9. Assess freedom for manufacture, import and export across each relevant jurisdiction.
10. Map third-party patents to potential licences and identify negotiation targets.
11. Evaluate the strength and validity of blocking patents to inform challenge-versus-licence decisions.
12. Establish an ongoing monitoring programme for newly published applications and grants.

Approaching EPO oppositions and UK revocation threats

FTO is not a one-off exercise. Monitoring competitor filings allows a defensive strategy to be built proactively, filing your own applications to occupy white space, preparing opposition dossiers against problematic third-party grants, and gathering prior art in advance of any dispute. Where a competitor patent threatens your product, the EPO opposition window offers a centralised route to challenge validity before the patent fragments into national rights. Coordinating EPO opposition with the possibility of UK revocation proceedings gives the broadest strategic flexibility.

Opposition, invalidity and enforcement practicalities at the EPO and in the UK

Because ADC patents are so valuable, they are heavily litigated, and any serious estate must be built to withstand attack as well as to assert.

EPO opposition strategy and timing

The EPO post-grant opposition procedure allows third parties to challenge a European patent centrally within the opposition period of nine months from the mention of grant. For ADC patents, opposition is often the opponent’s first and most efficient move, because a successful central revocation removes the patent in all designated states at once. For patentees, the corollary is to prepare for opposition from the drafting stage, building an enabling specification, securing well-supported fallback claims, and anticipating the lines of attack. Where opposition and national UK proceedings run in parallel, the interplay between the centralised EPO outcome and UK post-grant remedies must be managed carefully.

Typical attack lines against ADC patents

Opponents challenging antibody-drug conjugate patents uk typically deploy a recurring set of arguments:

• Lack of sufficiency. That a broad conjugate, functional antibody or linker-class claim is not enabled across its full scope by the examples provided.
• Lack of inventive step. That combining a known antibody, a known linker and a known payload was obvious, absent a surprising technical effect.
• Obviousness of linker or payload selection. That the chosen chemistry was a routine selection from well-characterised options.
• Added matter. That claim amendments during prosecution introduced subject matter not disclosed in the application as filed.

Litigation and injunction considerations

Enforcement decisions turn on which claims are infringed and how readily infringement can be proved. Product and composition claims are generally easier to enforce because the infringing article can be analysed directly; method and manufacturing claims, while harder to design around, present evidential challenges. In planning enforcement, consider the availability of interim relief, the strength of the claims most likely to be asserted, and the risk that litigation will trigger a validity counterattack. A well-constructed estate gives the patentee a choice of claims to assert, allowing the strongest and most readily proven to lead.

Comparison table, claiming strategies and trade-offs

Practical next steps and checklist for in-house teams

To convert this guidance into action, in-house teams managing antibody-drug conjugate patents uk should:

• Map the portfolio. Catalogue existing and planned patents across conjugate, antibody, linker, payload, conjugation and manufacturing.
• Decide SPC strategy early. Align regulatory and patent functions on which product will anchor an SPC before the marketing authorisation is finalised.
• Secure sequence compliance. Ensure sequence listings and any required deposits are complete and accurate for antibody claims.
• Build layered claims. Adopt the two-track strategy of broad composition claims plus narrow, well-enabled fallbacks.
• Schedule an FTO. Run the twelve-point FTO checklist well ahead of launch and update it as filings publish.
• Monitor competitors. Establish ongoing surveillance of new applications and grants to flag opposition and licensing opportunities.
• Plan licensing. Identify blocking rights early and decide between challenge, design-around and licence for each.
• Prepare for opposition. Draft every application anticipating a post-grant challenge, with enabling data and robust fallbacks.

General information only, not legal advice. Contact Global Law Experts for tailored advice on your specific circumstances.

Conclusion

Antibody-drug conjugate patents uk reward teams that plan early, draft defensively and treat patent and regulatory strategy as a single exercise. The combination nature of an ADC creates both opportunity, through layered protection across antibody, linker, payload, conjugation and manufacturing, and risk, through the sufficiency, inventive-step and added-matter attacks that opponents routinely deploy. With EPO and UKIPO practice continuing to evolve and SPC procedures developing following the UK’s departure from the EU, exclusivity and claim strategies set in earlier years should be revisited now.

A robust antibody-drug conjugate patents uk programme combines a well-supported two-track claim hierarchy, an early and carefully aligned SPC decision, and a disciplined freedom-to-operate review, the foundations on which durable, enforceable protection for these high-value therapeutics is built.

Sources

1. The Patents Act 1977 (UK)
2. European Patent Convention (EPC), European Patent Office
3. EPO Guidelines for Examination
4. UK Intellectual Property Office, Supplementary Protection Certificates guidance
5. The Human Medicines Regulations 2012
6. Medicines and Healthcare products Regulatory Agency (MHRA)
7. World Intellectual Property Organization (WIPO), Patents
8. Centre for Intellectual Property and Information Law (CIPIL), University of Cambridge